Mindray Medical downgraded to Neutral from Outperform at Credit Suisse Credit Suisse downgraded Mindray Medical due to the negative impact from its voluntary recall and the near-term impact on sales. Price target lowered to $32 from $34.
News For MR From The Last 14 Days
Check below for free stories on MR the last two weeks.
